Equity Profile

ALNY

Alnylam Pharmaceuticals, Inc.

Health CareBiotechnology$38.5B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Alnylam Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies based on RNA interference, which is a groundbreaking approach to treating genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales, crucial for long-term sustainability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ALNY Q2-2026 Earnings Preview

Context

Company Snapshot

Alnylam Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies based on RNA interference, which is a groundbreaking approach to treating genetic diseases. With a market cap of $38 billion, the company plays a significant role in the healthcare sector, particularly in innovative treatments that could change the landscape of medicine.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+157.23%

Avg Stock Reaction

+1.45%

Last Quarter Recap

In Q1-2026, Alnylam reported an EPS of $1.99, significantly surpassing estimates by nearly 118%. The stock reacted positively, gaining 2.76% the following day.

Management Promises & Guidance

Continued focus on advancing RNAi therapies.
Commitment to expanding clinical trials for new treatments.
Plans to improve operational efficiencies.

Expectations

Wall Street Expectations

Overall, expectations for Alnylam's upcoming earnings are mixed, with investors keenly awaiting updates on revenue and profitability metrics.

Bull Case

If Alnylam continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

On the other hand, any signs of revenue stagnation or failure to meet expectations could lead to a negative market reaction, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's strong history of EPS surprises, this number will be crucial for investor sentiment and stock performance.

How is revenue trending compared to previous quarters?

Revenue growth is essential for assessing the company's market position and future prospects, making it a key focus for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Alnylam's ability to sustain its growth trajectory, as evidenced by its consistent EPS surprises. The focus on RNAi therapies could lead to stronger revenue growth than anticipated.

Supporting Evidence

Alnylam has a 100% EPS beat rate in recent quarters, indicating strong operational performance.

The options market is pricing in a significant move, suggesting that traders expect volatility and potential upside.

Key Risk

If the company reports an EPS significantly above $2.10, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will indicate whether Alnylam can maintain its growth trajectory amid increasing market competition.

Bull Confirmed If

An EPS of $2.10 or higher would confirm strong operational performance and support the bull case.

Bear Confirmed If

An EPS below $1.50 would raise concerns about the company's profitability and could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±19.8%

Historical Avg

±6.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±19.8% while ALNY has averaged ±6.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

30.3%

Calls (21K)P/C Ratio: 0.89Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Alnylam beats expectations, history suggests a potential stock increase of around 1.45%, confirming strong operational momentum.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

A miss could lead to a decline, with historical patterns suggesting a drop of around 3.08% or more.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of clinical trials for new RNAi therapies.
2Details on revenue growth compared to previous quarters.
3Management's outlook on market competition and pricing strategies.
4Insights into operational efficiencies and cost management.
5Any new partnerships or collaborations that could enhance growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Alnylam Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies based on RNA interference, which is a groundbreaking approach to treating genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales, crucial for long-term sustainability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ALNY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+157.23%

Avg Stock Reaction

+1.45%

Last Quarter Recap

In Q1-2026, Alnylam reported an EPS of $1.99, significantly surpassing estimates by nearly 118%. The stock reacted positively, gaining 2.76% the following day.

Management Promises & Guidance

Continued focus on advancing RNAi therapies.
Commitment to expanding clinical trials for new treatments.
Plans to improve operational efficiencies.

Expectations

Wall Street Expectations

Overall, expectations for Alnylam's upcoming earnings are mixed, with investors keenly awaiting updates on revenue and profitability metrics.

Bull Case

If Alnylam continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

On the other hand, any signs of revenue stagnation or failure to meet expectations could lead to a negative market reaction, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's strong history of EPS surprises, this number will be crucial for investor sentiment and stock performance.

How is revenue trending compared to previous quarters?

Revenue growth is essential for assessing the company's market position and future prospects, making it a key focus for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

Supporting Evidence

Alnylam has a 100% EPS beat rate in recent quarters, indicating strong operational performance.

The options market is pricing in a significant move, suggesting that traders expect volatility and potential upside.

Key Risk

If the company reports an EPS significantly above $2.10, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will indicate whether Alnylam can maintain its growth trajectory amid increasing market competition.

Bull Confirmed If

An EPS of $2.10 or higher would confirm strong operational performance and support the bull case.

Bear Confirmed If

An EPS below $1.50 would raise concerns about the company's profitability and could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±19.8%

Historical Avg

±6.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±19.8% while ALNY has averaged ±6.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

30.3%

Calls (21K)P/C Ratio: 0.89Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Alnylam beats expectations, history suggests a potential stock increase of around 1.45%, confirming strong operational momentum.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

A miss could lead to a decline, with historical patterns suggesting a drop of around 3.08% or more.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of clinical trials for new RNAi therapies.
2Details on revenue growth compared to previous quarters.
3Management's outlook on market competition and pricing strategies.
4Insights into operational efficiencies and cost management.
5Any new partnerships or collaborations that could enhance growth.